Tags: experimental Alzheimer’s medicine | tau tangles in brain | bapineuzumab | Alzheimer's disease treatments | snarls of tau protein

Drug Reduces Alzheimer's Damage

Tuesday, 03 Apr 2012 07:24 AM

Johnson & Johnson and Pfizer Inc.’s experimental Alzheimer’s medicine may reduce the development of tau tangles in the brain, a hallmark trait of the degenerative condition, a small study suggested.

More than 5 million Americans have Alzheimer’s, a disease marked by the buildup of amyloid plaque and snarls of the tau protein. The drug bapineuzumab is being jointly developed by J&J and Pfizer to attack the disorder.

The study, reported in the Archives of Neurology, is the first to suggest it may work on the tau side of the disease. While the data showed no difference in beta amyloid levels, the drug reduced levels of a two forms of tau, according to the researchers from the University of Gothenburg in Sweden.

It’s not clear whether the changes will translate into a clinical benefit, the scientists said. The study analyzed cerebral spinal fluid for 27 patients treated with bapineuzumab and 19 given a placebo.

Results from the first pivotal trial designed to show if bapineuzumab can slow the progression of Alzheimer’s disease, rather than just ease its symptoms, is expected later this year. At least a dozen potential treatments for Alzheimer’s disease in mid- to late-stage testing have failed in the last decade.

J&J, based in New Brunswick, New Jersey, gained its share in the drug with its 2009 purchase of an 18 percent stake in Dublin-based Elan Corp. for $1 billion. Elan and Wyeth, which New York-based Pfizer acquired in 2009, funded the study.

SPECIAL: How One Deck of Cards Has Shown to Improve Memory

Copyright Bloomberg News

© HealthDay

1Like our page
An experimental Alzheimer's drug may cut the growth of tau protein tangles in the brain, a new study finds, and more research is planned to see if the medicine actually slows the disease's progression.
experimental Alzheimer’s medicine,tau tangles in brain,bapineuzumab,Alzheimer's disease treatments,snarls of tau protein
Tuesday, 03 Apr 2012 07:24 AM
Newsmax Inc.

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved